These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 25846577

  • 1. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
    Schernthaner G, Rosas-Guzmán J, Dotta F, Guerci B, Simó R, Festa A, Kiljański J, Zhou M, Gallwitz B.
    Diabetes Obes Metab; 2015 Jul; 17(7):689-98. PubMed ID: 25846577
    [Abstract] [Full Text] [Related]

  • 2. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
    Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, Basson BR, Festa A, Kiljański J, Sapin H, Trautmann M, Schernthaner G.
    Lancet; 2012 Jun 16; 379(9833):2270-8. PubMed ID: 22683137
    [Abstract] [Full Text] [Related]

  • 3. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
    Simó R, Guerci B, Schernthaner G, Gallwitz B, Rosas-Guzmàn J, Dotta F, Festa A, Zhou M, Kiljański J.
    Cardiovasc Diabetol; 2015 Sep 04; 14():116. PubMed ID: 26338040
    [Abstract] [Full Text] [Related]

  • 4. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.
    Violante R, Oliveira JH, Yoon KH, Reed VA, Yu MB, Bachmann OP, Lüdemann J, Chan JY.
    Diabet Med; 2012 Nov 04; 29(11):e417-24. PubMed ID: 22375612
    [Abstract] [Full Text] [Related]

  • 5. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL, Stewart J, Issa M, Lake B, Melis R.
    Clin Ther; 2005 Oct 04; 27(10):1535-47. PubMed ID: 16330290
    [Abstract] [Full Text] [Related]

  • 6. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA.
    Lancet Diabetes Endocrinol; 2016 Dec 04; 4(12):1004-1016. PubMed ID: 27651331
    [Abstract] [Full Text] [Related]

  • 7. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.
    Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D, Trautmann M.
    Diabetes Obes Metab; 2010 Dec 04; 12(12):1058-65. PubMed ID: 20977576
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, de Vries D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH, 4B Study Group.
    Diabetes Care; 2014 Oct 04; 37(10):2763-73. PubMed ID: 25011946
    [Abstract] [Full Text] [Related]

  • 10. The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics.
    Kazda C, Gallwitz B, Simó R, Guzmán JR, Kraus P, Nicolay C, Rose L, Schernthaner G.
    Diabetes Obes Metab; 2009 Dec 04; 11(12):1131-7. PubMed ID: 19758357
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J, Xiao W, Guo L, Li Q, Zhong L, Yang J, Yang J, Gao Y, Tian Q, Hong T.
    Acta Diabetol; 2020 Aug 04; 57(8):991-1000. PubMed ID: 32206903
    [Abstract] [Full Text] [Related]

  • 12. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Ridderstråle M, Rosenstock J, Andersen KR, Woerle HJ, Salsali A, EMPA-REG H2H-SU trial investigators.
    Diabetes Obes Metab; 2018 Dec 04; 20(12):2768-2777. PubMed ID: 29961998
    [Abstract] [Full Text] [Related]

  • 13. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
    Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, Foley JE, Zinman B.
    Diabetes Obes Metab; 2010 Sep 04; 12(9):780-9. PubMed ID: 20649630
    [Abstract] [Full Text] [Related]

  • 14. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.
    Diabetes Obes Metab; 2009 Feb 04; 11(2):157-66. PubMed ID: 19125777
    [Abstract] [Full Text] [Related]

  • 15. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
    Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME.
    Clin Ther; 2012 Oct 04; 34(10):2082-90. PubMed ID: 23031623
    [Abstract] [Full Text] [Related]

  • 16. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
    Abdul-Ghani M, Migahid O, Megahed A, Adams J, Triplitt C, DeFronzo RA, Zirie M, Jayyousi A.
    Diabetes Care; 2017 Mar 04; 40(3):325-331. PubMed ID: 28096223
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, Montanaro M, Fisher SA.
    Diabetes Obes Metab; 2014 May 04; 16(5):443-50. PubMed ID: 24205943
    [Abstract] [Full Text] [Related]

  • 19. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, EMPA-REG H2H-SU trial investigators.
    Lancet Diabetes Endocrinol; 2014 Sep 04; 2(9):691-700. PubMed ID: 24948511
    [Abstract] [Full Text] [Related]

  • 20. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
    Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.
    Ann Intern Med; 2007 Apr 03; 146(7):477-85. PubMed ID: 17404349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.